Entera Bio Ltd., established in June 2010 as a joint venture of fellow Israeli firms DNA Biomedical Solutions and Oramed Pharmaceuticals Inc., is seeking to raise up to $50 million, including overallotments, in an IPO, with a listing on Nasdaq under the ticker ENTX. The Jerusalem-based firm is developing oral formulations of teriparatide (parathyroid hormone, or PTH, 1-34) to treat hypoparathyroidism (EB-612) and osteoporosis (EB-613). Oppenheimer & Co. is the sole bookrunner on the deal, which was not priced.